Marianne Benn

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/3210087/publications.pdf

Version: 2024-02-01

118 papers	18,694 citations	36303 51 h-index	17592 121 g-index
131 all docs	131 docs citations	131 times ranked	28523 citing authors

#	Article	IF	Citations
1	Obesity increases heart failure incidence and mortality: observational and Mendelian randomization studies totalling over 1 million individuals. Cardiovascular Research, 2023, 118, 3576-3585.	3.8	16
2	Familial Hypercholesterolemia Prevalence Among Ethnicitiesâ€"Systematic Review and Meta-Analysis. Frontiers in Genetics, 2022, 13, 840797.	2.3	15
3	Plasma adiponectin and risk of asthma: observational analysis, genetic Mendelian randomisation and meta-analysis. Thorax, 2022, 77, 1070-1077.	5.6	6
4	LDL-Cholesterol versus Glucose in Microvascular and Macrovascular Disease. Clinical Chemistry, 2021, 67, 167-182.	3.2	7
5	Impact of high glucose levels and glucose lowering on risk of ischaemic stroke: a Mendelian randomisation study and meta-analysis. Diabetologia, 2021, 64, 1492-1503.	6.3	13
6	Atrial Fibrillation and Chronic Kidney Disease. European Heart Journal, 2021, 42, 2824-2826.	2.2	5
7	Low Plasma Adiponectin in Risk of Type 2 Diabetes: Observational Analysis and One- and Two-Sample Mendelian Randomization Analyses in 756,219 Individuals. Diabetes, 2021, 70, 2694-2705.	0.6	17
8	Global perspective of familial hypercholesterolaemia: a cross-sectional study from the EAS Familial Hypercholesterolaemia Studies Collaboration (FHSC). Lancet, The, 2021, 398, 1713-1725.	13.7	142
9	Causal Relationship between Plasma Adiponectin and Body Mass Index: One- and Two-Sample Bidirectional Mendelian Randomization Analyses in 460Â397 Individuals. Clinical Chemistry, 2020, 66, 1548-1557.	3.2	8
10	Repositioning of the global epicentre of non-optimal cholesterol. Nature, 2020, 582, 73-77.	27.8	138
11	Impact of glucose on risk of dementia: Mendelian randomisation studies in 115,875 individuals. Diabetologia, 2020, 63, 1151-1161.	6.3	25
12	Impact of Glucose Level on Micro- and Macrovascular Disease in the General Population: A Mendelian Randomization Study. Diabetes Care, 2020, 43, 894-902.	8.6	29
13	Type-2 diabetes and risk of dementia: observational and Mendelian randomisation studies in 1 million individuals. Epidemiology and Psychiatric Sciences, 2020, 29, e118.	3.9	33
14	Peripheral Neuropathyâ€"Time for Better Biomarkers?. Clinical Chemistry, 2020, 66, 638-640.	3.2	3
15	Low LDL Cholesterol by PCSK9 Variation Reduces Cardiovascular Mortality. Journal of the American College of Cardiology, 2019, 73, 3102-3114.	2.8	27
16	High Glucose Levels And Risk Of Vascular Diseases â€“ Observational And Mendelian Randomization Studies Of The General Population. Atherosclerosis, 2019, 287, e9.	0.8	0
17	Impact of LDL Cholesterol on Microvascular Versus MacrovascularÂDisease. Journal of the American College of Cardiology, 2019, 74, 1465-1476.	2.8	43
18	Response to Letter to the Editor: â€œFamilial Hypercholesterolemia and Risk of Peripheral Arterial Disease and Chronic Kidney Diseaseâ€• Journal of Clinical Endocrinology and Metabolism, 2019, 104, 3125-3126.	3.6	1

#	Article	IF	Citations
19	Causal Associations in Type 2 Diabetes Development. Journal of Clinical Endocrinology and Metabolism, 2019, 104, 1313-1324.	3.6	6
20	Combined Association of Body Mass Index and Alcohol Consumption With Biomarkers for Liver Injury and Incidence of Liver Disease. JAMA Network Open, 2019, 2, e190305.	5.9	21
21	Steroid receptor coactivator-1 modulates the function of Pomc neurons and energy homeostasis. Nature Communications, 2019, 10, 1718.	12.8	45
22	Relative effects of LDL-C on ischemic stroke and coronary disease. Neurology, 2019, 92, e1176-e1187.	1.1	40
23	257-OR: High Glucose Levels and Risk of Vascular Diseasesâ€"Observational Studies and Mendelian Randomization Studies of the General Population. Diabetes, 2019, 68, 257-OR.	0.6	0
24	From genome-wide association studies to Mendelian randomization: novel opportunities for understanding cardiovascular disease causality, pathogenesis, prevention, and treatment. Cardiovascular Research, 2018, 114, 1192-1208.	3.8	64
25	Relationship of Familial Hypercholesterolemia and High Low-Density Lipoprotein Cholesterol to Ischemic Stroke. Circulation, 2018, 138, 578-589.	1.6	56
26	Familial Hypercholesterolemia and Risk of Peripheral Arterial Disease and Chronic Kidney Disease. Journal of Clinical Endocrinology and Metabolism, 2018, 103, 4491-4500.	3.6	40
27	Overview of the current status of familial hypercholesterolaemia care in over 60 countries - The EAS Familial Hypercholesterolaemia Studies Collaboration (FHSC). Atherosclerosis, 2018, 277, 234-255.	0.8	163
28	Association ofLPAVariants With Risk of Coronary Disease and the Implications for Lipoprotein(a)-Lowering Therapies. JAMA Cardiology, 2018, 3, 619.	6.1	428
29	Protein-altering variants associated with body mass index implicate pathways that control energy intake and expenditure in obesity. Nature Genetics, 2018, 50, 26-41.	21.4	286
30	Rare and low-frequency coding variants alter human adult height. Nature, 2017, 542, 186-190.	27.8	544
31	Filaggrin lossâ€ofâ€function mutations as risk factors for ischemic stroke in the general population. Journal of Thrombosis and Haemostasis, 2017, 15, 624-635.	3.8	8
32	Genetic testing for familial hypercholesterolaemia is essential in individuals with high LDL cholesterol: who does it in the world?. European Heart Journal, 2017, 38, 1580-1583.	2.2	67
33	Whole-Genome Sequencing Coupled to Imputation Discovers Genetic Signals for Anthropometric Traits. American Journal of Human Genetics, 2017, 100, 865-884.	6.2	131
34	Exome-wide association study of plasma lipids in >300,000 individuals. Nature Genetics, 2017, 49, 1758-1766.	21.4	470
35	Low LDL cholesterol,PCSK9andHMGCRgenetic variation, and risk of Alzheimerâ€™s disease and Parkinsonâ€™s disease: Mendelian randomisation study. BMJ: British Medical Journal, 2017, 357, j1648.	2.3	143
36	Identification of new susceptibility loci for type 2 diabetes and shared etiological pathways with coronary heart disease. Nature Genetics, 2017, 49, 1450-1457.	21.4	218

#	Article	IF	Citations
37	High body mass index and cancer riskâ€"a Mendelian randomisation study. European Journal of Epidemiology, 2016, 31, 879-892.	5.7	43
38	PCSK9 R46L Loss-of-Function Mutation Reduces Lipoprotein(a), LDL Cholesterol, and Risk of Aortic Valve Stenosis. Journal of Clinical Endocrinology and Metabolism, 2016, 101, 3281-3287.	3.6	89
39	Lipoprotein(a) and familial hypercholesterolaemia â€“ Authors' reply. Lancet Diabetes and Endocrinology,the, 2016, 4, 730-731.	11.4	2
40	Components of the Metabolic Syndrome and Risk of Type 2 Diabetes. Journal of Clinical Endocrinology and Metabolism, 2016, 101, 3212-3221.	3.6	60
41	High lipoprotein(a) as a possible cause of clinical familial hypercholesterolaemia: a prospective cohort study. Lancet Diabetes and Endocrinology,the, 2016, 4, 577-587.	11.4	218
42	Sex Hormones and Ischemic Stroke: A Prospective Cohort Study and Meta-Analyses. Journal of Clinical Endocrinology and Metabolism, 2016, 101, 69-78.	3.6	71
43	Mutations causative of familial hypercholesterolaemia: screening of 98 098 individuals from the Copenhagen General Population Study estimated a prevalence of 1 in 217. European Heart Journal, 2016, 37, 1384-1394.	2.2	326
44	Plakophilin-2 c.419C>T and risk of heart failure and arrhythmias in the general population. European Journal of Human Genetics, 2016, 24, 732-738.	2.8	5
45	Response to the Letter: Response to â€œUse of biomarkers to identify new drug targets and to predict risk of cardiometabolic outcomesâ€•by Abasi A., et al. Journal of Clinical Endocrinology and Metabolism, 2016, 101, L22-L23.	3.6	0
46	No evidence that genetically reduced 25-hydroxyvitamin D is associated with increased risk of ischaemic heart disease or myocardial infarction: a Mendelian randomization study. International Journal of Epidemiology, 2015, 44, 651-661.	1.9	75
47	Extreme Concentrations of Endogenous Sex Hormones, Ischemic Heart Disease, and Death in Women. Arteriosclerosis, Thrombosis, and Vascular Biology, 2015, 35, 471-477.	2.4	51
48	Remnant Cholesterol, Low-Density Lipoprotein Cholesterol, and Blood Pressure as Mediators From Obesity to Ischemic Heart Disease. Circulation Research, 2015, 116, 665-673.	4.5	129
49	Subgroups at high risk for ischaemic heart disease:identification and validation in 67â€‰000 individuals from the general population. International Journal of Epidemiology, 2015, 44, 117-128.	1.9	5
50	The UK10K project identifies rare variants in health and disease. Nature, 2015, 526, 82-90.	27.8	1,014
51	Improved imputation of low-frequency and rare variants using the UK10K haplotype reference panel. Nature Communications, 2015, 6, 8111.	12.8	300
52	Obesity as a causal risk factor for deep venous thrombosis: a <scp>M</scp>endelian randomization study. Journal of Internal Medicine, 2015, 277, 573-584.	6.0	105
53	Authors' Response to: Skin cancer as a marker of sun exposure--a case of serious immortality bias. International Journal of Epidemiology, 2014, 43, 972-973.	1.9	2
54	Endogenous sex hormones and risk of venous thromboembolism in women and men. Journal of Thrombosis and Haemostasis, 2014, 12, 297-305.	3.8	47

#	Article	IF	Citations
55	Reply to Letters Regarding Article, â€œElevated Remnant Cholesterol Causes Both Low-Grade Inflammation and Ischemic Heart Disease, Whereas Elevated Low-Density Lipoprotein Cholesterol Causes Ischemic Heart Disease Without Inflammationâ€. Circulation, 2014, 129, e656.	1.6	1
56	Assessing Risk Prediction Models Using Individual Participant Data From Multiple Studies. American Journal of Epidemiology, 2014, 179, 621-632.	3.4	47
57	Authors' Response to: Skin cancer as a marker of sun exposure. International Journal of Epidemiology, 2014, 43, 1992-1993.	1.9	0
58	Antihypertensive treatment and risk of atrial fibrillation: a nationwide study. European Heart Journal, 2014, 35, 1205-1214.	2.2	92
59	Creatinine, eGFR and association with myocardial infarction, ischemic heart disease and early death in the general population. Atherosclerosis, 2014, 237, 67-75.	0.8	17
60	Remnant cholesterol as a cause of ischemic heart disease: Evidence, definition, measurement, atherogenicity, high risk patients, and present and future treatment. , 2014, 141, 358-367.		167
61	Susceptibility to Chronic Mucus Hypersecretion, a Genome Wide Association Study. PLoS ONE, 2014, 9, e91621.	2.5	25
62	ADH1B and ADH1C Genotype, Alcohol Consumption and Biomarkers of Liver Function: Findings from a Mendelian Randomization Study in 58,313 European Origin Danes. PLoS ONE, 2014, 9, e114294.	2.5	14
63	Response. Journal of the American College of Cardiology, 2013, 62, 1908-1909.	2.8	7
64	Remnant Cholesterol as a Causal Risk Factor for Ischemic Heart Disease. Journal of the American College of Cardiology, 2013, 61, 427-436.	2.8	768
65	YKL-40 levels and atrial fibrillation in the general population. International Journal of Cardiology, 2013, 167, 1354-1359.	1.7	30
66	Skin cancer as a marker of sun exposure associates with myocardial infarction, hip fracture and death from any cause. International Journal of Epidemiology, 2013, 42, 1486-1496.	1.9	36
67	Prevalence of family history in patients with reflex syncope. Journal of Clinical Neuroscience, 2013, 20, 692-696.	1.5	7
68	Low-density lipoprotein cholesterol and risk of gallstone disease: A Mendelian randomization study and meta-analyses. Journal of Hepatology, 2013, 58, 126-133.	3.7	22
69	25â€Hydroxyvitamin D and symptomatic ischemic stroke: An Original Study and Metaâ€Analysis. Annals of Neurology, 2013, 73, 38-47.	5.3	186
70	Exploring causal associations between alcohol and coronary heart disease risk factors: findings from a Mendelian randomization study in the Copenhagen General Population Study. European Heart Journal, 2013, 34, 2519-2528.	2.2	81
71	Elevated Remnant Cholesterol Causes Both Low-Grade Inflammation and Ischemic Heart Disease, Whereas Elevated Low-Density Lipoprotein Cholesterol Causes Ischemic Heart Disease Without Inflammation. Circulation, 2013, 128, 1298-1309.	1.6	402
72	<scp>AT</scp>₁ mutations and risk of atrial fibrillation based on genotypes from 71â€‰000 individuals from the general population. British Journal of Clinical Pharmacology, 2013, 76, 114-124.	2.4	7

#	Article	IF	Citations
73	25-HydroxyvitaminÂD concentrations and risk of venous thromboembolism in the general population with 18Â791 participants. Journal of Thrombosis and Haemostasis, 2013, 11, 423-431.	3.8	49
74	Association of plasma uric acid with ischaemic heart disease and blood pressure: mendelian randomisation analysis of two large cohorts. BMJ, The, 2013, 347, f4262-f4262.	6.0	228
75	Elevated Fibrinogen Levels Are Associated with Risk of Pulmonary Embolism, but Not with Deep Venous Thrombosis. American Journal of Respiratory and Critical Care Medicine, 2013, 187, 286-293.	5.6	50
76	Genetic variation in the parasympathetic signaling pathway in patients with reflex syncope. Genetics and Molecular Research, 2013, 12, 2601-2610.	0.2	8
77	The Age-Specific Quantitative Effects of Metabolic Risk Factors on Cardiovascular Diseases and Diabetes: A Pooled Analysis. PLoS ONE, 2013, 8, e65174.	2.5	496
78	Differences in autonomic balance in patients with cardioinhibitory and vasodepressor type of reflex syncope during head-up tilt test and active standing. Scandinavian Journal of Clinical and Laboratory Investigation, 2012, 72, 265-273.	1.2	9
79	The Effect of Elevated Body Mass Index on Ischemic Heart Disease Risk: Causal Estimates from a Mendelian Randomisation Approach. PLoS Medicine, 2012, 9, e1001212.	8.4	246
80	25-Hydroxyvitamin D Levels and Risk of Ischemic Heart Disease, Myocardial Infarction, and Early Death. Arteriosclerosis, Thrombosis, and Vascular Biology, 2012, 32, 2794-2802.	2.4	209
81	The plasma concentration of HDL-associated apoM is influenced by LDL receptor-mediated clearance of apoB-containing particles. Journal of Lipid Research, 2012, 53, 2198-2204.	4.2	39
82	Familial Hypercholesterolemia in the Danish General Population: Prevalence, Coronary Artery Disease, and Cholesterol-Lowering Medication. Journal of Clinical Endocrinology and Metabolism, 2012, 97, 3956-3964.	3.6	523
83	Genetic risk factors for ischaemic stroke and its subtypes (the METASTROKE Collaboration): a meta-analysis of genome-wide association studies. Lancet Neurology, The, 2012, 11, 951-962.	10.2	445
84	Nonfasting Glucose, Ischemic Heart Disease, and Myocardial Infarction. Journal of the American College of Cardiology, 2012, 59, 2356-2365.	2.8	67
85	Using genetic loci to understand the relationship between adiposity and psychological distress: a Mendelian Randomization study in the Copenhagen General Population Study of 53â€ƒ221 adults. Journal of Internal Medicine, 2011, 269, 525-537.	6.0	53
86	High platelet volume and increased risk of myocardial infarction: 39â€ƒ531 participants from the general population. Journal of Thrombosis and Haemostasis, 2011, 9, 49-56.	3.8	117
87	Nonfasting triglycerides, cholesterol, and ischemic stroke in the general population. Annals of Neurology, 2011, 69, 628-634.	5.3	95
88	Low-Density Lipoprotein Cholesterol and the Risk of Cancer: A Mendelian Randomization Study. Journal of the National Cancer Institute, 2011, 103, 508-519.	6.3	134
89	TRIB1 and GCKR Polymorphisms, Lipid Levels, and Risk of Ischemic Heart Disease in the General Population. Arteriosclerosis, Thrombosis, and Vascular Biology, 2011, 31, 451-457.	2.4	73
90	Screening of Three Novel Candidate Genes in Arrhythmogenic Right Ventricular Cardiomyopathy. Genetic Testing and Molecular Biomarkers, 2011, 15, 267-271.	0.7	18

#	Article	IF	Citations
91	Effect of ACE insertion/deletion and 12 other polymorphisms on clinical outcomes and response to treatment in the life study. Pharmacogenetics and Genomics, 2010, 20, 77-85.	1.5	33
92	Statistical methods for the time-to-event analysis of individual participant data from multiple epidemiological studies. International Journal of Epidemiology, 2010, 39, 1345-1359.	1.9	110
93	Wide spectrum of desmosomal mutations in Danish patients with arrhythmogenic right ventricular cardiomyopathy. Journal of Medical Genetics, 2010, 47, 736-744.	3.2	58
94	Missense Variants in <i>Plakophilin-2</i> in Arrhythmogenic Right Ventricular Cardiomyopathy Patients â€“ Disease-Causing or Innocent Bystanders?. Cardiology, 2010, 115, 148-154.	1.4	44
95	Genetic Variation in the Inwardly Rectifying K⁺ Channel Subunits <i>KCNJ3</i> (<i>GIRK1</i>) and <i>KCNJ5</i> (<i>GIRK4</i>) in Patients with Sinus Node Dysfunction. Cardiology, 2010, 115, 176-181.	1.4	14
96	PCSK9R46L, Low-Density Lipoprotein Cholesterol Levels, and Risk of Ischemic Heart Disease. Journal of the American College of Cardiology, 2010, 55, 2833-2842.	2.8	281
97	Does Elevated C-Reactive Protein Increase Atrial Fibrillation Risk?. Journal of the American College of Cardiology, 2010, 56, 789-795.	2.8	142
98	Diabetes mellitus, fasting blood glucose concentration, and risk of vascular disease: a collaborative meta-analysis of 102 prospective studies. Lancet, The, 2010, 375, 2215-2222.	13.7	3,807
99	Triglyceride-mediated pathways and coronary disease: collaborative analysis of 101 studies. Lancet, The, 2010, 375, 1634-1639.	13.7	606
100	Fasting and Nonfasting LDL Cholesterol: To Measure or Calculate?. Clinical Chemistry, 2009, 55, 845-847.	3.2	26
101	Apolipoprotein B levels, APOB alleles, and risk of ischemic cardiovascular disease in the general population, a review. Atherosclerosis, 2009, 206, 17-30.	0.8	96
102	Extreme Lipoprotein(a) Levels and Risk of Myocardial Infarction in the General Population. Circulation, 2008, 117, 176-184.	1.6	408
103	Mitochondrial Haplogroups. Circulation, 2008, 117, 2492-2501.	1.6	62
104	Common and Rare Alleles in Apolipoprotein B Contribute to Plasma Levels of Low-Density Lipoprotein Cholesterol in the General Population. Journal of Clinical Endocrinology and Metabolism, 2008, 93, 1038-1045.	3.6	37
105	Angiotensinogen and ACE gene polymorphisms and risk of atrial fibrillation in the general population. Pharmacogenetics and Genomics, 2008, 18, 525-533.	1.5	35
106	Impact of Hemoglobin on Plasma Pro-B-Type Natriuretic Peptide Concentrations in the General Population. Clinical Chemistry, 2007, 53, 1921-1927.	3.2	26
107	Improving Prediction of Ischemic Cardiovascular Disease in the General Population Using Apolipoprotein B. Arteriosclerosis, Thrombosis, and Vascular Biology, 2007, 27, 661-670.	2.4	135
108	Polymorphisms in Apolipoprotein B and Risk of Ischemic Stroke. Journal of Clinical Endocrinology and Metabolism, 2007, 92, 3611-3617.	3.6	18

#	Article	IF	Citations
109	Nonfasting Triglycerides and Risk of Myocardial Infarction, Ischemic Heart Disease, and Death in Men and Women. JAMA - Journal of the American Medical Association, 2007, 298, 299.	7.4	1,696
110	Polymorphism inAPOBAssociated with Increased Low-Density Lipoprotein Levels in Both Genders in the General Population. Journal of Clinical Endocrinology and Metabolism, 2005, 90, 5797-5803.	3.6	34
111	Phenotype of Heterozygotes for Low-Density Lipoprotein Receptor Mutations Identified in Different Background Populations. Arteriosclerosis, Thrombosis, and Vascular Biology, 2005, 25, 211-215.	2.4	38
112	Mutation in Apolipoprotein B Associated with Hypobetalipoproteinemia Despite Decreased Binding to the Low Density Lipoprotein Receptor. Journal of Biological Chemistry, 2005, 280, 21052-21060.	3.4	16
113	A reply. European Heart Journal, 2000, 21, 79-80.	2.2	2
114	Is QT dispersion a reliable index of heterogeneity of ventricular repolarization and a pro-arrhythmic marker?. European Heart Journal, 2000, 21, 79.	2.2	1
115	QT dispersion in patients with arrhythmogenic right ventricular dysplasia. European Heart Journal, 1999, 20, 764-770.	2.2	23
116	Dofetilide in patients with left ventricular dysfunction and either heart failure or acute myocardial infarction: Rationale, design, and patient characteristics of the DIAMOND studies. Clinical Cardiology, 1997, 20, 704-710.	1.8	100
117	Benign duodenocolic fistula. A case presenting with acidosis. Digestive Diseases and Sciences, 1997, 42, 345-347.	2.3	9
118	Infective endocarditis, 1984 through 1993: a clinical and microbiological survey. Journal of Internal Medicine, 1997, 242, 15-22.	6.0	84